Leading Element Driving Change in the Solid Tumor Testing Market in 2025: Growing Cancer Prevalence Drives Solid Tumor Testing Market Expansion Driver

How Are the key drivers contributing to the expansion of the solid tumor testing market?
The rise in cancer cases is predicted to drive the expansion of the solid tumor testing market in the future. This disease is characterized by abnormal cell growth and spread in the body. These aberrant cells, referred to as cancer cells, can invade neighboring tissues and organs, and may even distribute to different parts of the body through the bloodstream or lymph system. Approximately 90% of adult cancers manifest as solid tumors. Solid tumor testing is utilized to identify cancer cells in the blood of patients with solid tumors, even when the cancer cannot yet be detected through imaging tests. For example, in June 2023, a report by the Centers for Disease Control and Prevention, a public health agency in the US, revealed that there were 1,603,844 new cancer cases and 602,347 cancer-related fatalities in the US in 2020, with 403 new cancer instances and 144 cancer-linked deaths reported for every 100,000 individuals. Hence, the rising occurrence of cancer is fueling the expansion of the solid tumor testing market.

Get Your Solid Tumor Testing Market Report Here:
https://www.thebusinessresearchcompany.com/report/solid-tumor-testing-global-market-report

What growth opportunities are expected to drive the solid tumor testing market's CAGR through 2034?
Over recent years, the market size for solid tumor testing has significantly expanded. The market is set to grow from $27.96 billion in 2024 to $30 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.3%. Factors contributing to this growth in the historical period include the rise of personalized or precision medicine, challenges with tumor-specific drug delivery, limited therapeutic efficacy, high costs, and the simplifying tactics employed in cancer chemotherapies.

In the ensuing years, a robust escalation is predicted in the solid tumor testing market, with an estimated value of $40.06 billion by 2029 and a compound annual growth rate (CAGR) of 7.5%. This growth during the projection period is anticipated due to the escalating rate of cancer, improved healthcare structures, the advent of AI and IoT-based diagnostic apparatus, and an increase in government initiatives. Key trends forecasted during this period encompass progression in diagnostic tools, the unveiling of nanocarrier-based treatments, strategic partnerships, and the inception of next-generation testing devices.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

What are the most significant trends transforming the solid tumor testing market today?
Emerging innovations in liquid biopsy test solutions are swiftly becoming a predominant trend in the solid tumor testing market. Established companies in this field are strategizing to fortify their market position and garner a competitive edge by creating these advanced liquid biopsy test solutions. An illustration of this trend took place in June 2020 when the American-owned testing laboratory, NeoGenomics Inc., unveiled its inclusive range of three liquid biopsy tests for cancer patients with solid tumors. These tests, which are designed to detect cancerous cells in patients' blood even when the malignant form is not yet visible on imaging tests, can aid doctors make imperative decisions regarding future tests or treatment. Adding to its advantages, this modality is non-invasive, supports early detection, can be customized to each patient's treatment, and has received FDA approval. Notably, each of the introduced tests boasts a turnaround time of seven days or less, a feature that could potentially save significant time for clinicians.

Which growth-oriented segments of the solid tumor testing market are leading the industry's development?
The solid tumor testing market covered in this report is segmented -

1) By Type: Genetic Testing, Conventional Testing
2) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Cervical Cancer
3) By Application: Clinical, Research
4) By End-Users: Hospitals, Pharmaceutical And Biotechnology Companies, Contract Research Organizations, Academic Research Institutions

Subsegments:
1) By Genetic Testing: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Fluorescence In Situ Hybridization (FISH)
2) By Conventional Testing: Histopathology, Cytology, Imaging Techniques

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12658

What regions are leading the charge in the solid tumor testing market?
North America was the largest region in the solid tumor testing market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the solid tumor testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

What companies are at the forefront of innovation in the solid tumor testing market?
Major companies operating in the solid tumor testing market include Johnson & Johnson Ltd, Roche Diagnostics Corporation, Thermo Fisher Scientific Inc., Abbott Molecular Inc., Becton Dickinson And Company (BD), Quest Diagnostics Incorporated, Tosoh Corporation, Agilent Technologies Inc., bioMerieux Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN GmbH, Miltenyi Biotec GmbH, Natera Inc., Myriad Genetics Inc., Novocure Inc., Invitae Corporation, Guardant Health Inc., Foundation Medicine Inc., Epic Sciences Inc., Biocare Medical LLC, Agena Bioscience Inc., Caris Life Sciences Inc., 20/20 Gene Systems Inc., Grail Inc., Avant Diagnostics Inc., Genomic Testing Cooperative, Eutropics Pharmaceuticals Inc., Anixa Biosciences Inc., Cellular Biomedicine Group.

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=12658&type=smp

What Is Covered In The Solid Tumor Testing Global Market Report?

• Market Size Forecast: Examine the solid tumor testing market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the solid tumor testing market for a structured understanding.
• Key Players Overview: Analyze major players in the solid tumor testing market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the solid tumor testing market.
• Segment Contributions: Evaluate how different segments drive overall growth in the solid tumor testing market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the solid tumor testing market.
• Industry Challenges: Identify potential risks and obstacles affecting the solid tumor testing market.
• Competitive Landscape: Review strategic developments in the solid tumor testing market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.